References
- Lebwohl M, Rivera-Oyola R, Murrell DF. Should biologics for psoriasis be interrupted in the era of COVID-19? J Am Acad Dermatol. 2020;82(5):1217–1218.
- Conforti C, Giuffrida R, Dianzani C, et al. COVID-19 and psoriasis: is it time to limit treatment with immunosuppressants? A call for action. Dermatol Ther. 2020;e13298. DOI:https://doi.org/10.1111/dth.13298.
- Blaszczak A, Trinidad JCL, Cartron AM. Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: safety considerations. J Am Acad Dermatol. 2020;83(1):e31. DOI:https://doi.org/10.1016/j.jaad.2020.04.030.
- Bello SL, Serafino L, Bonali C, et al. Incidence of influenza-like illness into a cohort of patients affected by chronic inflammatory rheumatism and treated with biological agents. Reumatismo. 2012;64(5):299–306.
- Amerio P, Prignano F, Giuliani F, et al. COVID-19 and psoriasis: should we fear for patients treated with biologics? Dermatol Ther. 2020;e13434. DOI:https://doi.org/10.1111/dth.13434.
- Berkhout LC, l’Ami MJ, Ruwaard J, et al. Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay. Sci Transl Med. 2019;11(477):eaat3356. DOI:https://doi.org/10.1126/scitranslmed.aat3356.